SHANGHAI, Oct. 27, 2026 /PRNewswire/ -- Hengrui Pharma ("Hengrui" or "the Company") today announced its financial results for the first nine months of 2026. During this period, Hengrui reported revenue of RMB24.41 billion, representing a year-over-year increase of 5.26%. Product sales revenue was RMB21.48 billion, up 2.52% year-over-year. Net profit attributable to shareholders of the Company was RMB6.92 billion, up 20.38% year-over-year.